New hope for tough lymphoma: drug combo targets cancer cells
NCT ID NCT06357676
First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tests a combination of two drugs—glofitamab and ibrutinib—plus a pretreatment drug called obinutuzumab for people with mantle cell lymphoma who are 65 or older, or younger adults with high-risk features. The goal is to see if this combo is safe and can shrink or eliminate the cancer. About 27 participants will receive the treatment and be monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.